Mayo Clinic researchers, working with Virginia Tech, reported that metabolic dysfunction-associated steatotic liver disease (MASLD)—formerly called nonalcoholic fatty liver disease—comprises five biologically distinct subtypes, not a single uniform condition. Using clinical and genomic data from more than 4,600 patients, the team linked each subtype to different risks of complications such as advanced liver damage, heart disease, cancer, and the need for a liver transplant. Some pathways track closely with obesity and diabetes; others are driven more by inherited genetic differences and can progress even when classic metabolic risk factors are limited.
The findings, covered by ScienceDaily on October 18, 2026 and published in Nature Communications, also associate particular subtypes with conditions such as depression, sleep apnea, and migraine. The authors argue that separating the subtypes could support earlier screening and more tailored treatment, including studies of whether therapies like GLP-1 receptor agonists work differently across groups.
Source: ScienceDaily summary of Mayo Clinic / Nature Communications MASLD subtyping study (October 18, 2026); journal article Priya et al., Nature Communications (DOI: 10.1038/s41467-026-77410-6).
Image: Inferior surface of the liver from Gray’s Anatomy (Henry Vandyke Carter), public domain, via Wikimedia Commons.
Related answers
- What is DT-109, the experimental drug for severe fatty liver disease?
- Does eating late at night raise the risk of liver disease?
- What are hypoechoic liver masses?